Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Jul 31, 2025

SELL
$21.0 - $35.25 $412,209 - $691,922
-19,629 Closed
0 $0
Q2 2024

Jul 31, 2025

SELL
$18.86 - $23.55 $18,746 - $23,408
-994 Reduced 4.82%
19,629 $425,000
Q1 2024

Jul 31, 2025

BUY
$21.0 - $29.1 $32,571 - $45,134
1,551 Added 8.13%
20,623 $457,000
Q4 2023

Jul 31, 2025

SELL
$19.72 - $28.68 $13,764 - $20,018
-698 Reduced 3.53%
19,072 $524,000
Q3 2023

Jul 31, 2025

SELL
$22.33 - $29.92 $9,601 - $12,865
-430 Reduced 2.13%
19,770 $441,000
Q2 2023

Jul 31, 2025

SELL
$20.96 - $26.99 $11,884 - $15,303
-567 Reduced 2.73%
20,200 $514,000
Q1 2023

Jul 31, 2025

BUY
$20.58 - $27.89 $884 - $1,199
43 Added 0.21%
20,767 $463,000
Q4 2022

Feb 06, 2023

SELL
$15.31 - $29.94 $8,680 - $16,975
-567 Reduced 2.66%
20,724 $491,000
Q3 2022

Nov 01, 2022

BUY
$16.58 - $27.9 $36,907 - $62,105
2,226 Added 11.68%
21,291 $353,000
Q2 2022

Jul 18, 2022

SELL
$15.45 - $29.52 $22,139 - $42,302
-1,433 Reduced 6.99%
19,065 $379,000
Q1 2022

May 16, 2022

SELL
$21.94 - $42.51 $49,737 - $96,370
-2,267 Reduced 9.96%
20,498 $565,000
Q4 2021

Feb 08, 2022

SELL
$36.09 - $53.79 $41,106 - $61,266
-1,139 Reduced 4.76%
22,765 $938,000
Q2 2021

Aug 03, 2021

BUY
$32.94 - $56.62 $53,066 - $91,214
1,611 Added 7.23%
23,904 $956,000
Q1 2021

May 12, 2021

SELL
$44.47 - $81.38 $1.01 Million - $1.85 Million
-22,735 Reduced 50.49%
22,293 $1.2 Million
Q4 2020

Feb 16, 2021

BUY
$32.49 - $61.88 $716,956 - $1.37 Million
22,067 Added 96.11%
45,028 $2.2 Million
Q3 2020

Dec 03, 2020

BUY
$26.73 - $35.67 $613,747 - $819,018
22,961 New
22,961 $746,000

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $2.82B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Brinker Capital Investments, LLC Portfolio

Follow Brinker Capital Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brinker Capital Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Brinker Capital Investments, LLC with notifications on news.